Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Neoadjuvant mFOLFIRINOX and ELI002-7P Treatment With or Without Tislelizumab in Borderline and Resectable Pancreatic Ductal Adenocarcinoma

NCT07671339 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT07671339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07671339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Neoadjuvant mFOLFIRINOX and ELI002-7P Treatment With or Without Tislelizumab in Borderline and Resectable Pancreatic Ductal Adenocarcinoma
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
June 22, 2026
Completion date
June 30, 2028
Enrollment
20 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer